Erratum: Patients benefit from genetics-guided coumarin anticoagulant therapy (Clinical Pharmacology and Therapeutics (2014) 96:1 (15-17) DOI:10.1038/clpt.2014.44);Patients benefit from genetics-guided coumarin anticoagulant therapy

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 1, 2014, Pages 15-17

  Maitland Van Der Zee, A H ^a   Daly, A K ^b   Kamali, F ^b   Manolopoulous, V G ^c   Verhoef, T I ^a   Wadelius, M ^d   De Boer, A ^a   Pirmohamed, M ^e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; COUMARIN; PHENPROCOUMON; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CYP2C9 GENE; DRUG EFFICACY; DRUG SAFETY; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; VKORC1 GENE;

ACENOCOUMAROL; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; FEMALE; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PHENPROCOUMON; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84902689256     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.142     Document Type: Erratum

References (10)

1. Verhoef, T.I., Redekop, W.K., Daly, A.K., van Schie, R.M., de Boer, A. & Maitland-van der Zee, A.H. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br. J. Clin. Pharmacol. 77, 626-641 (2014)
2. Leendertse, A.J., Egberts, A.C., Stoker, L.J., van den Bemt, P.M.; HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch. Intern. Med. 168, 1890-1896 (2008)
3. Pirmohamed, M. et al.; EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369, 2294-2303 (2013)
4. Verhoef, T.I. et al.; EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N. Engl. J. Med. 369, 2304-2312 (2013)
5. Verhoef, T.I. et al.; EU-PACT Group. Long-Term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J. Thromb. Haemost. 10, 606-614 (2012)
6. Verhoef, T.I., Redekop, W.K., Hegazy, H., de Boer, A. & Maitland-van der Zee, A.H.; EU-PACT group. Long-Term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. J. Thromb. Haemost. 10, 2610-2612 (2012)
7. Kimmel, S.E. et al.; COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369, 2283-2293 (2013)
8. Hernandez, W. et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African-Americans. Pharmacogenomics J.; e-pub ahead of print 10 September 2013.
9. Howard, R. et al. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes. Clin. Chim. Acta 412, 2063-2069 (2011)
10. Nutescu, E.A. et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy 33, 1156-1164 (2013)